SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001213900-22-007086
Filing Date
2022-02-11
Accepted
2022-02-11 17:23:02
Documents
1
Group Members
VIVO CAPITAL LLCVIVO VENTURES FUND VI, L.P.VIVO VENTURES VI AFFILIATES FUND, L.P.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 5 TO SCHEDULE 13D ea155474-13da5vivo6_eiger.htm SC 13D/A 104727
  Complete submission text file 0001213900-22-007086.txt   106396
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Subject) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-87931 | Film No.: 22622847
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301
Business Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301 (650) 688-0818
Vivo Ventures VI, LLC (Filed by) CIK: 0001469547 (see all company filings)

IRS No.: 208829402 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SC 13D/A